Raptor Pharmaceutical Corp. Short Interest Up 7.3% in August (RPTP)
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) were the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 15,901,536 shares, a growth of 7.3% from the July 31st total of 14,819,552 shares, Stock Ratings Network reports. Currently, 27.3% of the shares of the company are sold short. Based on an average daily trading volume, of 929,597 shares, the short-interest ratio is presently 17.1 days.
In other Raptor Pharmaceutical Corp. news, Director Erich Sager sold 10,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $11.01, for a total transaction of $110,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 11.02 on Monday. Raptor Pharmaceutical Corp. has a one year low of $7.12 and a one year high of $17.72. The stock’s 50-day moving average is $9.77 and its 200-day moving average is $10.56. The company’s market cap is $691.4 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. The company had revenue of $16.31 million for the quarter, compared to the consensus estimate of $14.58 million. The company’s revenue for the quarter was up 77566.7% on a year-over-year basis. On average, analysts predict that Raptor Pharmaceutical Corp. will post $-0.74 earnings per share for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Receive News & Ratings for Raptor Pharmaceutical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.